SACCHI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.431
EU - Europa 13.321
AS - Asia 9.834
SA - Sud America 1.295
AF - Africa 231
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 17
Totale 48.167
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.190
GB - Regno Unito 6.342
CN - Cina 3.649
SG - Singapore 2.788
IT - Italia 1.745
HK - Hong Kong 1.488
SE - Svezia 1.320
BR - Brasile 1.080
DE - Germania 1.002
UA - Ucraina 753
RU - Federazione Russa 548
TR - Turchia 489
FI - Finlandia 441
VN - Vietnam 421
FR - Francia 333
KR - Corea 278
BG - Bulgaria 258
IN - India 148
CA - Canada 128
MA - Marocco 124
ID - Indonesia 114
IE - Irlanda 104
AR - Argentina 87
NL - Olanda 83
JP - Giappone 82
PL - Polonia 79
BD - Bangladesh 61
MX - Messico 60
ES - Italia 49
ZA - Sudafrica 43
MY - Malesia 42
BE - Belgio 39
CH - Svizzera 39
EC - Ecuador 36
IQ - Iraq 35
CZ - Repubblica Ceca 34
AU - Australia 30
LT - Lituania 30
IR - Iran 29
AT - Austria 28
CO - Colombia 28
PK - Pakistan 25
RO - Romania 22
TW - Taiwan 22
AE - Emirati Arabi Uniti 20
SA - Arabia Saudita 19
IL - Israele 18
CL - Cile 16
UZ - Uzbekistan 16
KE - Kenya 15
AZ - Azerbaigian 13
BZ - Belize 13
PE - Perù 13
VE - Venezuela 13
EU - Europa 12
PH - Filippine 12
PT - Portogallo 11
PY - Paraguay 11
EG - Egitto 10
TN - Tunisia 10
AL - Albania 9
JM - Giamaica 9
JO - Giordania 9
KZ - Kazakistan 9
HU - Ungheria 8
NO - Norvegia 8
NZ - Nuova Zelanda 8
HR - Croazia 7
KG - Kirghizistan 7
PA - Panama 7
NP - Nepal 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
GR - Grecia 5
TH - Thailandia 5
UY - Uruguay 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BH - Bahrain 4
BO - Bolivia 4
CR - Costa Rica 4
DZ - Algeria 4
ET - Etiopia 4
LB - Libano 4
LY - Libia 4
SN - Senegal 4
BN - Brunei Darussalam 3
GP - Guadalupe 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
CY - Cipro 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
MK - Macedonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
Totale 48.130
Salva come PNG Salva come JPEG
Città #
Southend 5.360
Santa Clara 2.176
Fairfield 2.102
Ashburn 1.770
Singapore 1.753
Woodbridge 1.524
Jacksonville 1.496
Hong Kong 1.481
Chandler 1.443
Hefei 1.213
Houston 1.206
Dearborn 1.033
Ann Arbor 1.031
Wilmington 808
Nyköping 756
Seattle 723
Cambridge 692
Beijing 676
London 597
Los Angeles 398
Chicago 328
Modena 314
Princeton 289
Seoul 267
New York 263
Eugene 261
San Diego 257
Sofia 255
Izmir 250
The Dalles 222
Des Moines 193
Moscow 164
Frankfurt am Main 160
Buffalo 158
Ho Chi Minh City 153
Helsinki 152
Council Bluffs 135
Milan 135
Salt Lake City 128
Munich 122
Shanghai 118
Casablanca 105
Dublin 99
Rome 96
San Jose 92
São Paulo 91
Columbus 90
Falls Church 86
Hanoi 85
Redwood City 78
Jakarta 74
Dallas 65
Boardman 62
Elk Grove Village 62
Bremen 60
Guangzhou 57
Norwalk 56
Warsaw 55
Fremont 49
Tampa 49
Nanjing 48
Phoenix 48
Turku 47
Tokyo 43
Brussels 38
Sterling 37
Kunming 36
Montreal 36
Toronto 35
Rio de Janeiro 33
Brooklyn 32
Jinan 32
Atlanta 31
Denver 30
Poplar 30
Turin 30
Belo Horizonte 29
Dong Ket 28
Lancaster 28
Naples 28
Boston 27
San Mateo 27
Orem 26
Tivoli 26
Kent 25
Verona 25
Brno 23
Changsha 23
Stockholm 23
Bologna 22
Johannesburg 22
Saint Petersburg 22
San Francisco 22
Wuhan 22
Nuremberg 21
Brasília 20
San Giuliano Milanese 20
Dhaka 19
Miami 19
Nanchang 19
Totale 35.125
Salva come PNG Salva come JPEG
Nome #
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 631
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 583
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 458
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 450
Utilità clinica del dosaggio della beta-tromboglobulina e del fattore piastrinico 4 409
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 401
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 388
Cinetica piastrinica e indicazione alla splenectomia nella porpora trombocitopenica idiopatica 370
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 367
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 357
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 356
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 351
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 345
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 337
Activity of BKM120 and BEZ235 against lymphoma cells 329
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 327
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 322
Leucemia eosinofila cronica: descrizione di un caso clinico a lunga sopravvivenza 321
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines 319
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 317
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 311
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 306
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 303
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 302
A concise review of lenalidomide therapy for follicular lymphoma 299
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 296
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 294
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 290
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 289
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience 280
Diagnosis of essential thrombocythemia at platele counts between 400 and 600x10(9)/L. 279
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 275
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 268
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 267
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 267
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 266
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 263
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 258
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 257
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 256
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 256
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 256
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 256
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 254
Alpha-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Group on ET 252
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 252
Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia 248
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 248
Chromosomes in paroxysmal nocturnal haemoglobinuria. 245
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 245
A PROSPECTIVE COMPARISON BETWEEN TREATMENT WITH PHLEBOTOMY ALONE AND WITH INTERFERON-ALPHA IN PATIENTS WITH POLYCYTHEMIA-VERA 244
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 243
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 242
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. 241
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 240
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 238
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 238
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 238
Epidermiological, diagnostic, therapeutic and prognostic aspects of essential thrombocithemia in a retrospective study of the GIMMC group in two thousand patients. 238
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 238
Isodicentric X chromosome in myeloproliferative disorders. 235
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 234
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 234
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 234
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 231
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 229
Acute nonlymphocytic leukemia with trisomy 4. 227
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 227
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 227
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 224
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 221
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4978 219
THE USE OF THE ALKALINE PHOSPHATASE-ANTIALKALINE PHOSPHATASE TECHNIQUE FOR IMMUNOPHENOTYPING ACUTE MYELOID-LEUKEMIA 219
Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects. 216
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 216
The Oral PKC-ß Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. 215
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 215
Leucemia e tricoleucociti: studio clinico patologico di 30 casi 214
Cromosomi marker ed anomalie nucleari nei linfociti di due pazienti con sindrome di Sezary/micosi fungoide. In problemi e prospettive nella medicina moderna. 214
Analysis of proliferation activity of myeloid leukaemia cell subsets in ANLL 213
Alterazione della regione p22-p23 del cromosoma 6 associata a sindrome mieloproliferativa (MPS). 213
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 212
Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. 211
Low-dose intravenous pepsin-treated gammaglobulin for idiopathic thrombocytopenic purpura in adults. 208
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 208
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors 208
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 208
All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi) 207
Descrizione di un metodo semplificato per lo studio della cinetica piastrinica 207
Non-Hodgkin Lymphoma in Psoriatic Arthritis Treated with Sequential, Multiple Anti-TNF-α Agents: A Case Report 207
Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression 207
Evaluation of platelet kinetics and some coagulation parameters in diabetic retinopathy. 206
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. 206
Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia 205
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 205
Sinus histiocytosis with massive lymphadenopathy. 205
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 204
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study 204
Su di un caso di plasmocitoma solitario extramidollare 202
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 200
Totale 26.873
Salva come PNG Salva come JPEG
Categoria #
all - tutte 174.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 174.153
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.662 0 0 0 0 0 310 372 544 231 550 421 234
2021/20224.305 114 538 357 443 160 285 188 264 481 280 582 613
2022/20234.224 523 480 272 401 462 745 92 390 510 41 198 110
2023/20242.701 123 154 168 209 617 214 461 275 57 47 108 268
2024/20258.470 328 86 112 616 1.717 1.195 626 412 1.010 429 785 1.154
2025/20268.658 1.064 785 1.423 1.856 2.245 1.285 0 0 0 0 0 0
Totale 48.448